Karnataka's Mangalya Bhagya scheme facilitates free mass wedding for 24 couples in Mysuru
MYSURU: Under the
Mangalya Bhagya
scheme, 24 couples tied the knot at a free mass wedding held at the
Srikanteshwara Temple
in
Nanjangud
town of Mysuru district on Thursday.
The event was part of the Karnataka government's initiative promoting simple weddings for economically disadvantaged families.
P. Shivaraju, Additional deputy commissioner, who presided over the mass wedding, emphasised the importance of financial prudence during life's milestones.
'There is no need to take loans for weddings. Simple ceremonies can set an example for others and prevent families from falling into debt,' he said.
Launched in 2020, Mangalya Bhagya is a flagship programme jointly organised by the District Administration and the Department of Hindu Religious Institutions and Charitable Endowments.
It aims to support poor and middle-income families by covering wedding expenses, ensuring that financial constraints don't stand in the way of a new beginning, the ADC stated.
Shivaraju expressed optimism about the growing impact of the initiative, stating, 'This year, 24 couples are beginning a new chapter without the burden of debt. We hope to see that number grow to at least 100 in the coming year.'
Srikantha, President of the
Nanjangud City Municipal Council
, echoed this sentiment, commending the programme as a 'thoughtful and practical approach' to reducing unnecessary expenditure and supporting community welfare.
'Such events bring dignity and convenience to families who might otherwise struggle to afford wedding costs,' he added.
The ceremony was also attended by Tahsildar Shivakumar Kasanur and
Jagadeesh Kumar
from Srikanteshwara Temple.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
7 hours ago
- Fashion Value Chain
Signify and BharatCares Partners to Illuminate 58 Gram Panchayats in Ayodhya, Uttar Pradesh, Benefiting over 2.4 Lakh People Under Har Gaon Roshan CSR initiative
In line with the #BrighterLivesBetterWorld vision, Signify, the world leader in lighting, announced a collaboration with BharatCares to bring sustainable outdoor lighting infrastructure to 58 Gram Panchayats across Uttar Pradesh under its Har Gaon Roshan CSR Program. This initiative aims to enhance safety, visibility, and the overall quality of life for people in these underserved areas, with a focus on rural communities. Signify and BharatCares partners to illuminate 58 Gram Panchayats in Ayodhya, Uttar Pradesh The project will see the installation of 2,000 streetlights. By supporting local infrastructure and rural development, the project will create a well-lit environment for residents, while fostering economic opportunities and improving daily life. The letter of commitment was exchanged between District Administration, Ayodhya and Signify in the presence of Smt. Anandiben Patel, the Hon'ble Governor of Uttar Pradesh, to further the sustainable development and community empowerment through innovative lighting solutions. Commenting on the partnership, Vikas Malhotra, Head of Connected Professional Business – Signify, Greater India, said, 'At Signify, we believe in bringing the best of innovations to the communities across India, through our Har Gaon Roshan CSR initiative. For this project, we are thankful for the support of BharatCares and the Hon'ble Governor of Uttar Pradesh for aiding our collective mission to strengthen rural communities. By illuminating these Gram Panchayats and installing 2,000 streetlights, we are enhancing the safety and visibility for people around these areas. This partnership reflects our commitment to using light to positively impact lives in the most underserved regions of India, fostering sustainable growth and community empowerment.' BharatCares representative Adarsh Trivedi, added, 'This partnership with Signify marks a significant step toward realizing our collective vision of transforming rural infrastructure in Uttar Pradesh. Providing lighting to these 58 Gram Panchayats will not only improve safety and infrastructure but also unlock new avenues for community development, economic growth, and enhance livelihood activities, especially during evening hours. This initiative will empower local communities and improve the overall well-being of its residents.' As Signify continues to expand its efforts across India, the initiative stands as a testament to the company's commitment to lighting up lives, building a brighter, more inclusive tomorrow through innovation that matters. About Signify Signify (Euronext: LIGHT) is the world leader in lighting for professionals, consumers and the Internet of Things. Our Philips products, Interact systems and data-enabled services deliver business value and transform life in homes, buildings and public spaces. In 2024, we had sales of EUR 6.1 billion, approximately 29,000 employees and a presence in over 70 countries. We unlock the extraordinary potential of light for brighter lives and a better world. We have been in the Dow Jones Sustainability World Index since our IPO for eight consecutive years and have achieved the EcoVadis Platinum rating for five consecutive years, placing Signify in the top one percent of companies assessed. News from Signify can be found in the Newsroom, on X, LinkedIn and Instagram. Information for investors is located on the Investor Relations page.
Economic Times
5 days ago
- Economic Times
Piramal Healthcare targets $2 bn revenue by FY30, to focus on organic expansion: Chairperson Nandini Piramal
Agencies About 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and Japan. Piramal Healthcare will focus on organic expansion as its primary growth driver for the next 4-5 years, while it looks for licensing of product acquisition deals in both complex hospital generics and consumer healthcare business, chairperson Nandini Piramal told ET in an reiterated the company's revenue target of $2 billion by FY30 despite macroeconomic volatility and sector-specific headwinds.'Our network of facilities is well-balanced and as people think about diversifying supply chains, and even think of going back to the US, I think we are well set for that. Our focus on differentiated offerings such as antibody-drug conjugate (ADCs) is seeing growth. Overall, the other businesses are also on track for that growth,' she is an area of pharmaceutical research that focuses on creating targeted cancer therapies. Talking about the current global headwinds, Piramal said near-term macro-economic uncertainty and biotech funding volatility in the US are some of the significant risk factors to watch out for in the months ahead. On Monday, the company announced its first quarter results with a net loss of Rs 82 crore in Q1 FY26 versus net loss of Rs 89 crore a year ago. Revenue from operations fell 1% year-on-year to Rs 1,934 crore. EBITDA margin for Q1 FY26 was 9% versus 11% in Q1 FY25, primarily impacted by inventory destocking. This was partly offset by improved profitability of the overseas facilities in the CDMO 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and ahead, Piramal said growth will be balanced between India, US and UK. The focus will be on broadening the customer base and getting new company is investing $90 million to expand two of its US facilities in Lexington and Lexington capability will come online in 2027, she said, and play a vital role in the company's integrated antibody-drug conjugate (ADC) development and manufacturing program.
Time of India
6 days ago
- Time of India
Piramal Healthcare targets $2 bn revenue by FY30, to focus on organic expansion: Chairperson Nandini Piramal
Piramal Healthcare will focus on organic expansion as its primary growth driver for the next 4-5 years, while it looks for licensing of product acquisition deals in both complex hospital generics and consumer healthcare business, chairperson Nandini Piramal told ET in an interaction. She reiterated the company's revenue target of $2 billion by FY30 despite macroeconomic volatility and sector-specific headwinds. Explore courses from Top Institutes in Please select course: Select a Course Category others Project Management Management Technology Product Management Finance Public Policy PGDM Degree Data Science Design Thinking Artificial Intelligence MBA Cybersecurity MCA healthcare Leadership Healthcare Digital Marketing Data Science Others Operations Management Data Analytics CXO Skills you'll gain: Duration: 16 Weeks Indian School of Business CERT - ISB Cybersecurity for Leaders Program India Starts on undefined Get Details 'Our network of facilities is well-balanced and as people think about diversifying supply chains, and even think of going back to the US, I think we are well set for that. Our focus on differentiated offerings such as antibody-drug conjugate (ADCs) is seeing growth. Overall, the other businesses are also on track for that growth,' she said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Wakefield: This Is The Truth About "No Fuss" Cremations Golden Leaves Undo ADC is an area of pharmaceutical research that focuses on creating targeted cancer therapies. Talking about the current global headwinds, Piramal said near-term macro-economic uncertainty and biotech funding volatility in the US are some of the significant risk factors to watch out for in the months ahead. Live Events On Monday, the company announced its first quarter results with a net loss of Rs 82 crore in Q1 FY26 versus net loss of Rs 89 crore a year ago. Revenue from operations fell 1% year-on-year to Rs 1,934 crore. EBITDA margin for Q1 FY26 was 9% versus 11% in Q1 FY25, primarily impacted by inventory destocking. This was partly offset by improved profitability of the overseas facilities in the CDMO business. About 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and Japan. Going ahead, Piramal said growth will be balanced between India, US and UK. The focus will be on broadening the customer base and getting new projects. The company is investing $90 million to expand two of its US facilities in Lexington and Riverview. The Lexington capability will come online in 2027, she said, and play a vital role in the company's integrated antibody-drug conjugate (ADC) development and manufacturing program.
